IL-28A Polyclonal Antibody, Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIPA599854-Each-of-1 | In Stock | ₹ 46,502.50 |
PIPA599854 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 46,502.50
GST (18%): ₹ 8,370.45
Total Price: ₹ 54,872.95
Antigen
IL-28A
Classification
Polyclonal
Conjugate
Unconjugated
Gene
IFNL2
Gene Alias
cytokine Zcyto20, EG330496, Ifnl2, IFN-lambda2, IFN-lambda-2, Il28a, IL-28A, ILN, interferon lambda 2, interferon lambda-2, interferon, lambda 2, interferon-lambda 2, interferon-lambda2, Interleukin, interleukin 28A, interleukin 28A (interferon, lambda 2), interleukin-28A, ZCYTO20
Host Species
Rabbit
Purification Method
Affinity chromatography
Regulatory Status
RUO
Gene ID (Entrez)
282616
Content And Storage
-20°C
Form
Liquid
Applications
Immunocytochemistry, Western Blot
Concentration
1 mg/mL
Formulation
PBS with 50% glycerol and 0.02% sodium azide; pH 7.4
Gene Accession No.
Q8IZJ0
Gene Symbols
IFNL2
Immunogen
A synthesized peptide derived from human IFNL2(Accession Q8IZJ0), corresponding to amino acid residues M1-G33.
Quantity
100 μL
Primary or Secondary
Primary
Target Species
Human
Product Type
Antibody
Isotype
IgG
Related Products
Description
- Antibody detects endogenous levels of total IL28A
- IL-28A belongs to the IFN lambda family, a novel family of cytokines within the IL-10 superfamily
- The three members of this family are IL-29 (IFN lambda 1), IL-28A (IFN lambda 2), and IL-28B (IFN lambda 3), and are also known as the type III Interferons.The IFN lambdas signal through a heterodimeric receptor of which one subunit, IL-10R2, is shared with other members of the superfamily
- The second subunit, IFN lambda R1 or IL-28R alpha, is unique to the IFN lambdas
- Signaling occurs through the Jak/STAT pathway in a similar manner as the type I IFN (IFN alpha/beta) and activates many of the same genes despite low sequence homology between the cytokines and receptors in the two families
- Both IFN families display antiviral activity through the induction of antiviral protein production in target cells and the upregulation of MHC class I expression
- These proteins also exhibit antiproliferative and antitumor effects, making them a possible alternative to IFN alpha cancer therapies
- Unlike the type I IFN, which are able to stimulate most cells, response to IFN lambda stimulation appears to be limited to dendritic and some tumor cells due to the limited expression of IFN lambda R1
- Another notable difference is the ability of the IFN lambda stimulation to drive dendritic cells towards the production of CD4+CD25+FoxP3+ regulatory T cells, suggesting a possible immunoregulatory role